Gamma Knife Center Ecuador (DFC-2020-GAMMAKNIFECEN)

  • Ecuador
Where the impacts of the investment may be experienced.
Financial Institutions
  • US International Development Finance Corporation (DFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Bank Risk Rating
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Gamma Knife Ecuador
The holder of the loan, grant, or other investment.
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 3.17 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Primary Source

Original disclosure @ DFC website

Updated in EWS Jul 13, 2020

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

This Project involves a seven-year, $3.375 million OPIC loan to Gamma Knife Ecuador to finance the acquistion of outstanding equity ownership, upgrade of equipment, and working capital for an existing brain cancer treatment facility and unique clinic named Gamma Knife Center Ecuador located in Guayaquil, Ecuador (the :Project:). The Borrower offers medical services to detect and treat certain types of brain tumors, arteriovenous malformations, and other brain dysfunctions using cutting edge technology, that is both extremely accurate and has above average therapeutic response, and highly-qualified and experienced medical staff. The Project’s total cost is expected to be $3.75 million, with the remaining financing coming from the investors in the form of equity. In 2009, a Leksell Gamma Knife Machine Model 4C was acquired by the Project from Elekta, which is the Swedish Company that owned the patent and developed new medical technologies, such as the non-invasive medical procedures that uses radioactive Cobalt-60. The first patient was succesfully treated in October 2011. Since 2011, the Borrower has treated more than 1,000 patients and intends to upgrade or replace their current machine and resources within one year. The new technology implemented through the project will be Leksell Gamma Knife Machine New Model Perfexion recently developed by Elekta for an estimated cost of $1.5 million available in the market.

Investment Description
  • US International Development Finance Corporation (DFC)
Private Actors
Contact Information

The "Contact Information" was not available at the moment of the snapshot.